期刊
BMJ OPEN
卷 11, 期 2, 页码 -出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/bmjopen-2020-045543
关键词
leukaemia; adverse events; paediatrics; chemotherapy
资金
- Danish Children's Cancer Foundation [2017-2082, 2019-5966]
- Danish Cancer Society [R192-A11.590]
- Cancer Survivorship and General Late effects (CASTLE) [F-2 23 724-03]
- Danish Cancer Research Foundation [FID20823]
- NordForsk [91 172]
- Engineer Otto Christensen's Foundation [101459]
- University of Aarhus
- Holm's Memorial Foundation [20 006-1975]
- AP Moeller Foundation [18-L-0225 L-0225]
- Farmer of Oelufgaard Memorial Foundation
- Skagen Teddy Bear Museum
This study aims to establish a Nordic, national childhood ALL survivor cohort to investigate the somatic and psychosocial treatment-related burden and associated risk factors. Primary endpoints include the cumulative incidence and burden of 197 health conditions, while secondary endpoints focus on organ-specific outcomes and psychosocial outcomes.
Introduction More than 90% of patients diagnosed with childhood acute lymphoblastic leukaemia (ALL) today will survive. However, half of the survivors are expected to experience therapy-related chronic or late occurring adverse effects, reducing quality of life. Insight into underlying risk trajectories is warranted. The aim of this study is to establish a Nordic, national childhood ALL survivor cohort, to be investigated for the total somatic and psychosocial treatment-related burden as well as associated risk factors, allowing subsequent linkage to nation-wide public health registers. Methods and analysis This population-based observational cohort study includes clinical follow-up of a retrospective childhood ALL survivor cohort (n=475), treated according to a common Nordic ALL protocol during 2008-2018 in Denmark. The study includes matched controls. Primary endpoints are the cumulative incidence and cumulative burden of 197 health conditions, assessed through self-report and proxy-report questionnaires, medical chart validation, and clinical examinations. Secondary endpoints include organ-specific outcome, including cardiovascular and pulmonary function, physical performance, neuropathy, metabolic disturbances, hepatic and pancreatic function, bone health, oral and dental health, kidney function, puberty and fertility, fatigue, and psychosocial outcome. Therapy exposure, acute toxicities, and host genome variants are explored as risk factors. Ethics and dissemination The study is approved by the Regional Ethics Committee for the Capital Region in Denmark (H-18035090/H-20006359) and by the Danish Data Protection Agency (VD-2018-519). Results will be published in peer-reviewed journals and are expected to guide interventions that will ameliorate the burden of therapy without compromising the chance of cure.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据